Tuesday, July 22, 2014

MYOS Corp. Tackles Muscles Health - Zacks Initiation of Coverage

By Jason Napodano, CFA & David Bautz, PhD

On July 21, 2014, Zacks SCR initiated coverage of MYOS Corporation (MYOS) with a 'Buy' rating and $20 price target. A link to our full 21 research report can be found here >> REPORT.

We have also written an article for Seeking-Alpha.
  • MYOS Corporation is a biotherapeutics and bionutrition company focused on improving muscle health and function to combat muscle related diseases.
  • We believe a solid scientific basis differentiates MYOS from other bionutrition companies.
  • Rapidly increasing revenues are helping to provide the necessary capital for research initiatives targeting muscle health.
  • The company just recently listed on the NASDAQ. MYOS has a clean capital structure and strong management.
  • We believe MYOS would make a good investment for those looking to get into the emerging area of muscle health. We see the shares fairly valued at $20.
Please see the full article on Seeking-Alpha's website here >> ARTICLE.

Any questions, please let me know!

Tuesday, July 15, 2014

For Avita, 'NICE' Decision In September Could Be Huge

By Jason Napodano, CFA
  • The UK's MTAC is expected to meet on July 17th to review data on Avita Medical's ReCell for the treatment of burns and scalds.
  • A positive recommendation to MTAC to NICE would facilitate reimbursement of ReCell in the UK, opening up a huge market and setting a precedent for the rest of Europe.
  • ReCell is a simple to use and effective product for the treatment of a number of skin defects. Sales, however, are limited by lack of reimbursement.
  • A decision by NICE is expected in September 2014.
Please read the full article on Seeking-Alpha: LINK

As always, if you have any questions please let me know!

Thursday, July 10, 2014

#AskAMBS Twitter Chat A Nice Success For Amarantus Bio

By Jason Napodano, CFA

On July 10, 2014, Amarantus Bioscience Holdings, Inc. (AMBS) CEO, Gerald Commissiong, held a "Twitter Chat" that started at 4:00PM EDT. The chat lasted for approximately 45 minutes and was a big success in our view given the large number of participants and breadth of questions asked by investors. Below we have highlighted some of the questions asked by investors and answers by Mr. Commissiong. Investors can access the entire chat on Twitter by searching the hashtag #AskAMBS.

We expect this to be around mid-August 2014.

More on the LymPro data expected at AAIC can be found HERE

More on the MANF development plan can be found HERE

More on the MANF opportunities in both RP and Wolframs can be found HERE

Kudos to Mr. Commissiong and Amarantus for hosting this open forum and answering as many questions from investors as possible. We applaud the effort by the company, as well as the format. Retail investors don't often get an opportunity to interact directly with the CEO of a publicly trading company. TheStreet.com biotech columnist Adam Feuerstein summed it up nicely: